Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, September 1999, p. 725-728, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A New Method with General Diagnostic Utility for
the Calculation of Immunoglobulin G Avidity
Maria H.
Korhonen,1
John
Brunstein,1
Heikki
Haario,2,3
Alexei
Katnikov,3
Roberto
Rescaldani,4 and
Klaus
Hedman1,*
Haartman Institute, Department of
Virology,1 and Department of
Mathematics,2 University of Helsinki, and
ProfMath Ltd.,3 Helsinki, Finland, and
Ospedale S. Gerardo Di Monza, Monza, Italy4
Received 22 February 1999/Returned for modification 13 April
1999/Accepted 16 June 1999
 |
ABSTRACT |
The reference method for immunoglobulin G (IgG) avidity
determination includes reagent-consuming serum titration. Aiming at better IgG avidity diagnostics, we applied a logistic model for the
reproduction of antibody titration curves. This method was tested with
well-characterized serum panels for cytomegalovirus, Epstein-Barr
virus, rubella virus, parvovirus B19, and Toxoplasma gondii. This approach for IgG avidity calculation is generally applicable and attains the diagnostic performance of the reference method while being less laborious and twice as cost-effective.
 |
INTRODUCTION |
The diagnosis of acute viral and
some other microbial infections often relies on the serological
detection of immunoglobulin M (IgM) antibodies, but the available
techniques have serious pitfalls that may lead to erroneous
interpretations (3, 4, 9, 11). This problem is of particular
importance for infections during the first trimester of pregnancy,
which should be diagnosed as exactly as possible (8, 10,
18). The differential assay of high-avidity and low-avidity IgG
antibodies can be used as an alternative or a complement to the IgM
antibody assay and is gaining popularity as a diagnostic method for the
assessment of the time of infection. In protein-denaturing avidity
enzyme immunoassays (EIAs), the patient's IgG (e.g., in serum) is
allowed to bind to its antigen, followed by elution with or without a
protein denaturant, such as urea. From the proportion of IgG remaining antigen bound, the time of primary infection can be deduced.
The most straightforward procedure for the calculation of avidity is a
comparison of EIA absorbances in single (fixed) dilutions of serum.
This procedure is quite sensitive and specific for the diagnosis of
several different microbes (3, 6, 7, 13, 17, 18) but is
affected to some extent by the concentration of specific IgG
(7). The two-step avidity assay developed by Lecolier and
Pucheu is based on the selection of working dilutions according to the
level of specific IgG in each specimen (12). Another means
of improved avidity calculation is based on the
method, in which
the antibody titer is derived from a single dilution of serum by use of
the formula log10 titer =
(OD
), in
which OD is optical density and
and
are constants specified by
the assay manufacturer for each batch of kit reagents (5, 19). The avidity technique based on end-point titration of IgG (2, 8, 10, 11, 16, 17) is not influenced by IgG concentration but is relatively laborious and reagent consuming. Due to
its excellent sensitivity and specificity, we consider this approach
the reference method for several microbes (9). Aiming at low
cost combined with high performance, we have applied a logistic
procedure (14) for avidity calculation; here, we evaluate
its diagnostic value.
 |
MATERIALS AND METHODS |
Serum panels.
The cytomegalovirus (CMV) panel contained sera
from three groups. Group 1 comprised 91 sera from 48 patients with
primary CMV infections verified by IgM-positive seroconversion of CMV IgG (Cytomegalovirus IgG EIA Kit; Labsystems, Helsinki, Finland). Group
2 contained 88 sera from 29 patients with exogenous reinfection or
endogenous reactivation. The criteria were a
4-fold increase in the
CMV IgG concentration in a serum pair, with a high avidity of CMV IgG
(1) but no CMV IgM in the first sample. The 44 sera constituting group 3 were collected from asymptomatic members of the
laboratory staff, all of which had tested CMV IgG positive at least 1 year earlier.
The Epstein-Barr virus (EBV) panel comprised 34 sera from 25 EBV
IgM-positive (EBV IFA Test; Gull Laboratories, Salt Lake City, Utah)
and EBV IgG-positive (Enzygnost Anti-EBV/IgG; Dade Behring, Marburg,
Germany) patients. The cardinal symptoms were mononucleosis,
tonsillitis, lymphadenitis, and fever. Controls were 19 sera from
asymptomatic members of the laboratory staff shown to be EBV IgG
positive at least 1 year earlier.
The rubella virus panel consisted of 121 samples from patients with
primary infections and of 40 control samples shown to be seropositive
at least 2 years earlier (7).
The parvovirus panel contained 128 sera from 68 patients with a B19
primary infection (17). Control samples were 56 sera from 34 B19 IgG-positive, B19 IgM-negative asymptomatic members of the
laboratory staff with seropositivity documented for at least 2 years.
The 500 sera making up the Toxoplasma gondii serum panel had
been studied at Ospedale S. Gerardo Di Monza, unlike the others described above. This panel was divided in two subgroups. The first
subgroup consisted of 420 sera from 267 IgM-positive (Abbott) and
IgG-positive (Labsystems) patients. The second subgroup comprised 80 control sera, 40 of which had, upon prior measurement, shown a high
avidity and 40 of which had shown a low avidity.
In this study, IgG avidities for the respective pathogens were measured
with the Cytomegalovirus IgG EIA Kit; the Enzygnost Anti-EBV/IgG kit
with a mixture of viral capsid antigen (VCA), Epstein-Barr nuclear
antigen (EBNA), and early antigen (EA) sequences as the antigen; and
the Rubella IgG Avidity Kit (Labsystems). The avidity of B19 IgG was
measured with the recombinant VP1 antigen EIA (17), and the
avidity of toxoplasma IgG was measured with the Toxoplasma
gondii IgG Avidity Kit (Labsystems). Titration curves were drawn
(i) according to the reference method (8) with 4+4 dilutions
per sample (i.e., one series of four dilutions washed with urea and
another series of four dilutions washed without urea), (ii) from the
same EIA data sets (4+4 dilutions per sample) with a curve-fitting
software based on logistic functions (see below), (iii) with the same
logistic model but with only 2+2 dilutions per sample, and (iv) from
the same data sets with a log-log model. Avidity was calculated as the
ratio of IgG titers: (titer with urea/titer without urea) × 100.
Logistic model.
A curve-fitting Win-95 computer program was
developed for reproduction of the shapes of IgG titration curves. The
fitting curve was, in its basic form, a so-called logistic function,
f(x) = 1/[1 + exp(
x)], which was,
however, parametrized into the form f(x) = (a + b)/{1 + exp[
(x
c)/d]}. Here, exp
was the exponential function and x was the logarithm of the
dilution ratio. The to-be-fitted variables a, b, c, and
d were given certain limits beforehand that were based on
avidity calculations performed earlier in our laboratory. For example,
we know that f(x) = 0 for sufficiently large values of
x. Also, from the absorbance value measured at the first
dilution, an approximative limit for f(0) could be deduced. This value represents the theoretical maximum value of the titration curve with no dilution. Thus, only two parameters had to be fitted for
each curve.
Log-log model.
For comparison with the logistic model, a
piece of software which functions by linear interpolation of
log(absorbance) versus log(dilution) values for native and denatured
samples was developed. The end-point titer of both samples was
calculated, and the ratio of end-point titers was taken to be the
output avidity result. In fact, this process amounted to using the
function log[f(x)] = a(x) + b for the curve fitting
instead of the logistic function. As above, x was the
logarithm of the dilution ratio.
 |
RESULTS |
In the reference method, EIA absorbances were plotted against
serum dilutions on a semilogarithmic scale, and the individual data
points (4+4 dilutions per sample) were united by straight lines (Fig.
1A). Under the same conditions with 4+4
serum dilutions, the logistic model produced curvilinear, or
"smooth," IgG titration curves, which often bypassed individual
data points (Fig. 1B). With 2+2 serum dilutions per sample, the same
logistic model produced IgG titration curves that resembled those
obtained with 4+4 serum dilutions (Fig. 1C) but, at the curve ends, met
their data points precisely. The log-log model displayed linear IgG
titration curves when both axes were linear (Fig. 1D).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 1.
End-point titration curves for CMV IgG avidity
determinations. Views are as seen on the computer screen. In each curve
pair, the upper one was obtained without urea and the lower one was
obtained with urea. Calculations were done with the reference method
and 4+4 data points (dilutions of serum) (A), with the logistic model
and 4+4 data points (B) and 2+2 data points (C), and with the log-log
model and 2+2 data points. This CMV IgG is of low avidity. PBST,
phosphate-buffered saline containing 0.05% Tween 20.
|
|
The logistic model operating with 2+2 dilutions per sample was tested
with all the serum panels, and the results were compared with
those obtained with the reference method (operating with 4+4 data
points). Overall, the two methods showed excellent correlation; the correlation coefficients for all four viruses and the one protozoan
were
0.94 (Fig. 2). Also illustrated
are the domains (bordered by broken lines) in which the avidity values
obtained could be allowed to move without a change in diagnosis. For
the >1,000 samples studied, only once, in the parvovirus serum panel, was there disagreement between the two methods; the reference method
produced a pathological value of low avidity (12%), whereas the 2+2
logistic method produced a nonpathological value of high avidity
(26%). This single crossover was due to a deviant EIA data point
caused by an apparent pipetting error; however, this error was well
tolerated by the 4+4 logistic method, which produced a
borderline-avidity result (17%).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of IgG avidity results calculated with the
reference method (horizontal axis) and with the curve-fitting methods
(vertical axis). (A to D and F) Results obtained with the logistic
model. (E) Results obtained with the log-log model. (A) CMV
(correlation coefficient [r], 0.96). (B) EBV (r,
0.96). (C) Rubella virus (r, 0.95). (D) Parvovirus B19
(r, 0.94). (E) T. gondii (r, 0.93).
(F) T. gondii (r, 0.96). The broken lines mark
the thresholds between low-borderline and borderline-high avidities.
Crossovers from low to high avidity in panels D and E are marked by
arrows.
|
|
The diagnostic value of the simple log-log model was determined with
the large toxoplasma serum panel. As depicted in Fig. 2E, this model
also corresponded fairly well to the reference method, yielding only
two false high-avidity results. However, the logistic model (with 2+2
data points) was even more accurate (r, 0.96), producing no
false avidity results and fewer crossovers to or from the borderline
avidity zone (Fig. 2F).
 |
DISCUSSION |
We applied and evaluated curve-fitting methods for IgG avidity
calculations. The diagnosis of four viruses (a nonenveloped single-stranded DNA virus, an enveloped single-stranded RNA virus, and
two enveloped double-stranded DNA viruses) and one protozoan could be
accomplished reliably with the logistic model and only 2+2 dilutions
per sample. Success with T. gondii, an immunologically and
structurally complex pathogen, is particularly noteworthy because
simple indices obtained from single dilutions of serum are insufficient
for its avidity determination (7, 8). Given previously
published work (15), we were somewhat surprised to observe
that the diagnostic performance of the log-log model lagged behind that
of the more elaborate logistic model only slightly. The explanation may
arise from the fact that in avidity determinations, two parallel (with
and without a protein denaturant) titration curves are generated by the
same model, the inherent errors of which are abolished when the two
titration end-point values are divided.
In conclusion, the logistic approach for IgG avidity calculations is
generally applicable, attains the diagnostic performance of the
reference method, and is twice as cost-effective.
 |
ACKNOWLEDGMENTS |
We thank Lea Hedman for expert technical assistance.
This work was supported by the Helsinki University Central Hospital
Research and Education Fund, the Finnish Technology Advancement Fund,
the Center for International Mobility, and the Sohlberg Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Haartman
Institute and HUCH Diagnostic, Department of Virology, P.O. Box 21 (Haartmaninkatu 3), FIN-00014 University of Helsinki, Helsinki,
Finland. Phone: 358-9-1912 6473. Fax: 358-9-1912 6491. E-mail:
klaus.hedman{at}helsinki.fi.
 |
REFERENCES |
| 1.
|
Aalto, S. M.,
K. Linnavuori,
H. Peltola,
E. Vuori,
B. Weissbrich,
J. Schubert,
L. Hedman, and K. Hedman.
1998.
Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
J. Med. Virol.
56:186-191[Medline].
|
| 2.
|
Andersson, A.,
V. Vetter,
L. Kreutzer, and G. Bauer.
1994.
Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology.
J. Med. Virol.
43:238-244[Medline].
|
| 3.
|
Bodeus, M.,
S. Feyder, and P. Goubau.
1998.
Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infection in pregnant women.
Clin. Diagn. Virol.
9:9-16.
[Medline] |
| 4.
|
de Ory, F.,
I. Casas,
C. J. Domingo, and J. M. Echevarria.
1995.
Application of fluoroimmunoassay to the identification of low avidity specific IgG against pathogenic human viruses and Toxoplasma gondii.
Clin. Diagn. Virol.
3:323-332.
|
| 5.
|
Dopatka, H. D., and B. Giesendorf.
1992.
Single point quantification of antibody by ELISA without need of a reference curve.
J. Clin. Lab. Anal.
6:417-422[Medline].
|
| 6.
|
Grangeot-Keros, L.,
M. J. Mayaux,
P. Lebon,
F. Freymuth,
G. Eugene,
R. Stricker, and E. Dussaix.
1997.
Value of cytomegalovirus (CMV) avidity index for the diagnosis of primary CMV infection in pregnant women.
J. Infect. Dis.
175:944-946[Medline].
|
| 7.
|
Hedman, K., and I. Seppälä.
1988.
Recent rubella virus infection indicated by a low avidity of specific IgG.
J. Clin. Immunol.
8:214-221[Medline].
|
| 8.
|
Hedman, K.,
M. Lappalainen,
I. Seppälä, and O. Mäkelä.
1989.
Recent primary toxoplasma infection indicated by a low avidity of specific IgG.
J. Infect. Dis.
159:736-740[Medline].
|
| 9.
|
Hedman, K.,
M. Lappalainen,
M. Söderlund, and L. Hedman.
1993.
Avidity of IgG in serodiagnosis of infectious diseases.
Rev. Med. Microbiol.
4:123-129.
|
| 10.
|
Jenum, P.,
B. Stray-Pedersen, and A.-G. Gundersen.
1997.
Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity.
J. Clin. Microbiol.
35:1972-1977[Abstract].
|
| 11.
|
Lappalainen, M.,
P. Koskela,
M. Koskiniemi,
P. Ämmälä,
V. Hiilesmaa,
K. Teramo,
K. O. Raivio,
J. Remington, and K. Hedman.
1993.
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG.
J. Infect. Dis.
167:691-697[Medline].
|
| 12.
|
Lecolier, B., and B. Pucheu.
1993.
Intérêt de l'étude de l'avidité des IgG pour le diagnostic de la toxoplasmose.
Pathol. Biol.
41:155-158[Medline].
|
| 13.
|
Lutz, E.,
K. N. Ward,
R. Szyldo, and J. M. Goldman.
1996.
Cytomegalovirus antibody avidity in allogenic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
J. Med. Virol.
49:61-65[Medline].
|
| 14.
|
Maciel, R. J.
1985.
Standard curve fitting in immunodiagnostics: a primer.
J. Clin. Immunol.
8:98-106.
|
| 15.
|
Plikaytis, B. D.,
S. H. Turner,
L. L. Gheesling, and G. M. Carlone.
1991.
Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
29:1439-1445[Abstract/Free Full Text].
|
| 16.
|
Sensini, A.,
S. Pascoli,
D. Marchetti,
R. Castronari,
M. Marangi,
G. Sbaraglia,
C. Cimmino,
A. Favero,
M. Castelletto, and A. Mottola.
1996.
IgG avidity in the serodiagnosis of acute Toxoplasma gondii infection: a multicenter study.
Clin. Microbiol. Infect.
2:25-29.
[Medline] |
| 17.
|
Söderlund, M.,
C. S. Brown,
B. J. Cohen, and K. Hedman.
1995.
Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity.
J. Infect. Dis.
171:710-713[Medline].
|
| 18.
|
Thomas, H. I. J., and P. Morgan-Capner.
1991.
The use of antibody avidity measurements for the diagnosis of rubella.
Rev. Med. Virol.
1:41-50.
|
| 19.
|
Weissbrich, B.
1998.
The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis.
J. Med. Virol.
54:145-153[Medline].
|
Clinical and Diagnostic Laboratory Immunology, September 1999, p. 725-728, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Colombo, F. A., Vidal, J. E., Oliveira, A. C. P. d., Hernandez, A. V., Bonasser-Filho, F., Nogueira, R. S., Focaccia, R., Pereira-Chioccola, V. L.
(2005). Diagnosis of Cerebral Toxoplasmosis in AIDS Patients in Brazil: Importance of Molecular and Immunological Methods Using Peripheral Blood Samples. J. Clin. Microbiol.
43: 5044-5047
[Abstract]
[Full Text]
-
Petersen, E., Borobio, M. V., Guy, E., Liesenfeld, O., Meroni, V., Naessens, A., Spranzi, E., Thulliez, P.
(2005). European Multicenter Study of the LIAISON Automated Diagnostic System for Determination of Toxoplasma gondii-Specific Immunoglobulin G (IgG) and IgM and the IgG Avidity Index. J. Clin. Microbiol.
43: 1570-1574
[Abstract]
[Full Text]
-
Revello, M. G., Gerna, G.
(2002). Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin. Microbiol. Rev.
15: 680-715
[Abstract]
[Full Text]
-
Prince, H. E., Wilson, M.
(2001). Simplified Assay for Measuring Toxoplasma gondii Immunoglobulin G Avidity. CVI
8: 904-908
[Abstract]
[Full Text]
-
Marcolino, P. T., Silva, D. A. O., Leser, P. G., Camargo, M. E., Mineo, J. R.
(2000). Molecular Markers in Acute and Chronic Phases of Human Toxoplasmosis: Determination of Immunoglobulin G Avidity by Western Blotting. CVI
7: 384-389
[Abstract]
[Full Text]